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Background: Prior studies report that monoamine oxidases inhibitors (MAO-I) when used
as an adjunct to levodopa ameliorate motor symptoms in Parkinson’s disease (PD), but this
was not tested in relation to cognitive or psychiatric measures.
Objective: Here, we tested the effects of MAO-I as an adjunct to levodopa, in comparison
to levodopa or dopamine (DA) agonists alone, on various cognitive, affective and quality of
life measures.
Methods: We studied three groups of subjects: healthy controls, PD patients on combined
levodopa and MAO-I, and PD patients on levodopa or DA agonists only.
Results: We found that compared to monotherapy, combined MAO-I and levodopa
seemed to improve cognition, including probabilistic learning, working memory and
executive functions. There were no differences between the different medication regimes
on deterministic learning, attention or memory recall. It was also found that MAO-I as an
adjunct to levodopa improves affective measures such as depression, apathy, anxiety and
quality of life. Interestingly, this enhancing effect of combined levodopa and MAO-I was
more pronounced in PD patients with severe akinesia, compared to patients with severe
tremor.
Conclusion: Our data are in agreement with (a) the Continuous Dopaminergic Stimulation
(CDS) theory which states that continuous stimulation of the basal ganglia enhances motor,
psychiatric and cognitive functions in PD patients; and/or (b) findings that MAO-I increase
the bioavailability of monoamines that have beneficial effects on motor and behavioral
dysfunction in PD.
Keywords: Parkinson’s disease, MAO inhibitors, cognition, working memory, depression, anxiety, quality of life,
learning
INTRODUCTION
PHARMACOLOGICAL THERAPY FOR PARKINSON’S DISEASE
Parkinson’s disease (PD) is a progressive and neurodegenerative
movement disorder associated with a substantial loss of dopamine
(DA) neurons in the substantia nigra (Kish et al., 1988), which
are essential for regulating the function of the striatum (a major
input structure of the basal ganglia), and the control of voluntary
movement.
Standard pharmacological medications for PD include lev-
odopa, various kinds of DA agonists, and Monoamine Oxi-
dases Inhibitors (MAO-I), among others. These medications are
prescribed as either monotherapy (taken alone) or polytherapy
(using more than one medication in combination) (Rinne, 1987).
Levodopa is a DA precursor, taken up by DA cells and converted
into DA (Trugman et al., 1991; Muriel et al., 2002; Grace, 2008).
MAO- I are a class of chemicals that inhibit the activity of
monoamine oxidase enzymes, thus preventing the breakdown of
monoamine neurotransmitters, including DA (O’Carroll et al.,
1983; Dewey, 2004; Robottom, 2011). MAO-B inhibitors are often
administered in the earlier stages of PD, including selegiline and
rasagiline. Both these drugs are used either as monotherapy or
in combination with levodopa (Caslake et al., 2009; Riederer and
Laux, 2011; Fabbrini et al., 2012). While the beneficial effects of
these drugs on the motor symptoms of PD are well established,
their effects on cognitive and affective symptoms are not as
thoroughly investigated.
EFFECTS OF MAO-B INHIBITORS ON MOTOR, COGNITIVE, AND
AFFECTIVE PROCESSES IN PARKINSON’S DISEASE
As monotherapy, MAO-B inhibitors may be more effective at the
early stages of PD and can delay the need for levodopa. When
taken in combination with levodopa (especially as it is usually
done in advanced stages of PD), they are known to prolong
the effectiveness of levodopa, reduce the amount of levodopa
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required to control the symptoms and reduce motor fluctuations
(Henchcliffe et al., 2005; Riederer and Laux, 2011). While the
effectiveness of selegiline in controlling the motor symptoms of
PD has been reported as early as 1975 with the first clinical trial by
Birkmayer et al. (1975), the effect of rasagiline on motor processes
was recently confirmed by several large multicenters as well as
smaller clinical trials (Parkinson Study Group, 2002; Olanow
et al., 2009). Notable among these studies which used rasagiline
as a monotherapy are the ADAGIO and TEMPO studies. The
TEMPO study showed the effectiveness of rasagiline on motor
processes (as measured by the UPDRS scores), over a 26-week
double blind placebo controlled clinical trial on 404 patients
with early PD (Parkinson Study Group, 2002). Further, the
ADAGIO study noted that 1 mg of MAO-B-I might have a disease
modifying effect as observed in activities of daily living scale and
the rate of change in the UPDRS scale (Olanow et al., 2009).
Importantly, a recent meta-analysis study found that MAO-B
inhibitors as an adjunct to levodopa is superior to levodopa alone
at reducing PD symptoms in PD patients (Talati et al., 2009).
Research on the effect of MAO Inhibitors on cognitive, behav-
ioral as well as emotional functions in PD has been limited. Most
of these studies focus on the effectiveness of the drugs to reduce
neuropsychiatric symptoms (Hindmarch et al., 1992; Parkinson
Study Group, 1993; Elmer et al., 2006). MAO-B inhibitors such as
moclobemide, tranylcypromine, seligiline, and rasagiline (taken
alone or in combination with other antidepressants) have been
found to be useful in treating depression and anxiety in PD
(Steur and Ballering, 1997; Fahn and Chouinard, 1998; Nayak
and Henchcliffe, 2008; Korchounov et al., 2012).
Due to its amphetamine-like derivatives, MAO-B Inhibitors
have been suggested to improve cognitive performance in
cognitively-impaired rats and other subjects (Yasar et al., 1996).
Studies conducted on mouse models with derivatives of MAO
Inhibitors have shown neuroprotective effects that additionally
lend support to the hypothesis of the potential of MAO inhibitors
in affecting cognitive, behavioral and emotional measures in
patients with PD (Youdim, 2006, 2013; Kupershmidt et al., 2012).
Further, Nickel et al. (1990) have shown that in rats, l-deprenyl
and l-amphetamine (metabolites of MAOC-I, such as selegiline)
increase EEG theta rhythms, indicating that the drug has facilitory
effects on learning and memory.
The purpose of this present study is to examine the com-
bined effects of MAO-B inhibitors and levodopa vs. monotherapy
involving either DA agonists or levodopa on the motor, psychi-
atric, and cognitive processes in patients with PD. For this we
designed an exploratory study where we recruited three groups of
subjects: healthy controls, PD patients on MAO-I and levodopa,
and PD patients on levodopa or DA agonists only. All groups were
tested on various cognitive, neuropsychological, and affective
processes, as described below.
METHODS
SUBJECTS
The study was approved by the local medical ethics commit-
tee, and informed consent was obtained from all subjects, in
compliance with research standards for human research at Ain
Shams and Cairo Universities. All subjects were recruited from
the clinics associated with the Institute of Psychiatry, Ain Shams
University as well as Cairo University. The patients diagnosed by
a neurologist as having idiopathic PD according to UK Brain
Bank diagnostic criteria for PD and they were in three differ-
ent treatment regimes such as: (1) a monotherapy of levodopa;
(2) monotherapy of DA agonists; and (3) combined therapy
of levodopa and MAO- I (selegiline or rasagiline). PD patients
were assigned different medications to manage their symptoms
(tremor, akinesia, gait disturbance, and postural instability). Most
patients were initially prescribed levodopa. If levodopa did not
manage the symptoms (e.g., based on patients’ distress or care-
giver’s observations), they were given MAO-I in addition to it.
Some patients were taken off levodopa and assigned DA agonists
to manage their symptoms.
We tested healthy controls, PD patients on levodopa and
MAO-I (selegiline or rasagiline), and PD patients on monother-
apy (levodopa or DA agonists only), using a between-subject
design (see Table 1). Among PD patients on monotherapy, 35
subjects were on levodopa while 4 subjects were on DA agonists
only (Pramipexole and requip). Among 37 PD patients on lev-
odopa and MAO-I, 19 patients were on selegiline and levodopa
and were 18 patients on rasagiline and levodopa. In neurological
and clinical practice, the dosage of each selegiline and rasagiline is
different. Most of our patients were on daily dose of selegiline of
10 mg (except one patient was on 20 mg daily dose); other patients
were on daily dose of either 0.5 or 1 mg of rasagiline. As in our
prior studies (Moustafa et al., 2008a,b; Piray et al., 2014), most of
our healthy control subjects were spouses of patients, who tended
to be fairly well matched demographically. Other healthy control
subjects were recruited from the community. The total testing
time took approximately 105–120 min for healthy controls, and
115–135 min for PD patients (over two sessions of testing).
Each patient’s disease severity was measured using the Hoehn
and Yahr stages (Hoehn and Yahr, 1967) and the Unified Parkin-
son’s Disease Rating Scale (UPDRS).The severity of freezing of
gait episodes was measured using the Freezing of Gait Question-
naire (FOGQ; Giladi et al., 2000) and The National Adult Reading
Test was used to measure the premorbid intellectual functioning
(predicted intelligence quotient (IQ); Bright et al., 2002).
All subjects were screened for intact general cognitive function
and absence of dementia with the Mini-Mental Status Exam
(MMSE; Folstein et al., 1975) and were required to obtain a
score of at least 26 to be considered for the study. Patients who
were on combined levodopa and DA agonist therapy, choliner-
gic, or serotonergic medications were excluded. Altogether, nine
subjects were excluded based on these criteria. In addition, two
subjects did not learn one of the learning tasks, so their data
was not included in the statistical analysis. Subjects who were
on multiple levodopa and DA agonists were also excluded from
further testing. The final study sample consisted of 43 healthy
controls, 37 PD patients on MAO-I and levodopa, and 39 PD
patients on monotherapy, which is either levodopa or DA agonists
only (see Table 1). Levodopa equivalent daily dose (LEDD) was
calculated as in prior studies (Hobson et al., 2005; Ecker et al.,
2009; Weintraub et al., 2010; Moustafa et al., 2013).
The motor symptoms of the selected patients varied. Therefore
to avoid this factor confounding the results, we categorized the
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Table 1 | Subject demographic, clinical and data for healthy controls, PD patients on MAO-I and levodopa, and PD patients on monotherapy
(levodopa or dopamine agonists only).
PD Patients on MAO-I and Ldopa PD Patients on Ldopa or DA agonists only Healthy Controls P-value
N 37 39 43
Age 65.2 (4.6) 67.3 (4.3) 66.9 (5.2) 0.304
Sex (M/F) 26/11 27/12 29/14 0.48
PD (akinetic-rigid/Tremor) 21/16 22/17 – 0.734
Education (years) 13.1 (2.3) 12.9 (2.2) 13.2 (3.1) 0.21
NART-predicted IQ 109.5 (12.7) 114.5 (13.1) 116.5 (9.7) 0.53
MMSE 27.4 (1.1) 27.7 (1.4) 28.2 (1.9) 0.420
NAART 34.2 (11.8) 34.8 (11.4) 36.9 (7.3) 0.312
H and Y 2.61 (0.4) 2.53 (0.5) – 0.601
UPDRS 18.9 (5.9) 23.8 (5.2) – 0.094
FOGQ 2.6 (0.6) 3.1 (0.7) – 0.09
Disease duration 8.61 (4.1) 8.46 (3.8) – 0.732
Values here represent Mean (S.D). Abbreviations: H and Y, Hoehn and Yahr staging of PD; NAART, North American Adult Reading Test; MMSE, Mini-Mental State
Examination; FOGQ, Freezing of Gait Questionnaire; UPDRS, Unified Parkinson’s Disease Rating Scale.
subjects into tremor-predominant and akinetic-rigid subtypes,
using their scores on the UPDRS and included the motor symp-
toms as an independent variable in the analysis. Specifically, a
ratio was computed based on the UPDRS part III tremor score
(average for items 20 and 21) and the mean UPDRS akinetic/rigid
score (average for items 22–27 and 31). A ratio of >1.0 was
considered tremor-dominant, <0.80 akinetic-rigid and 0.80–1.0
mixed. Subjects with mixed rigidity-akinesia and tremor (for
similar methods used to subtype patients, see Jankovic et al., 1990;
Vakil and Herishanu-Naaman, 1998; Poletti et al., 2012) were
excluded from the study.
One-way ANOVA was used to compare demographic and
neuropsychological measures between the PD patients on MAO-I
and levodopa, PD patients on monotherapy, and healthy control
subjects. Chi square statistic was used to compare the gender ratio
and the PD type (akinesia vs. tremor-dominant), between the
medicated PD patients, unmedicated PD patients, and healthy
controls groups (Table 1). There was no significant difference
between the groups on any of the demographic or motor mea-
sures. Although statistically nonsignificant, patients on MAO-
I and levodopa had lesser motor dysfunction (as measured
by UPDRS) and gait abnormalities (as measured by FOGQ)
than the patients who was on a monotherapy of levodopa
(Table 1).
BEHAVIORAL TASKS AND SCALES
All subjects performed two learning tasks in a counterbalanced
order. All tasks were administered on a PC laptop computer.
Probabilistic learning task
Subjects were administered a computer-based probabilistic learn-
ing task. On each trial, subjects viewed one of six stimuli, and
were instructed to make a right or left button-press (e.g., response
X or Y). The feedback was probabilistic. So, a correct response
results in either gaining points or no feedback with 20 and 80%
probability, respectively. An incorrect response results in gaining
points or no feedback with 80 and 20% probability, respectively.
The correct response (X or Y) varies across stimuli, and the task
had 120 trials.
Deterministic learning task
The deterministic learning task was similar to the probabilistic
learning task, except that the stimuli were different and the
stimulus-feedback relationship was deterministic (i.e., stimuli
were 100% predictive of a feedback).
Neuropsychological assessment
We used the following tests to measure neuropsychological func-
tions such as verbal and visual attention, learning and memory,
working memory as well as executive functions.
Trail making test- A and B (Reitan and Wolfson, 1985). This
test which consists of a set of numbered and lettered dots which
a subject must connect as fast as possible in a serial order. The
test consists of two parts, with Part B requiring more cognitive
flexibility than Part A. The test provides information about visual
attention, scanning, speed of processing and mental flexibility, a
component of executive functioning.
Digit span test (D. Wechsler, 1958). This test taken from the
Wechsler Adult Intelligence Scale (Digit Span forward and back-
ward) assesses verbal attention and working memory. The subject
has to recall immediately a set of numbers presented in either the
order in which it was presented or in a backward order. In this
study, both forward and backward tests were administered.
Controlled oral word association test (Troyer et al., 1997). This
test which assesses verbal fluency requires a subject to generate
words starting with the letters F, A and S. In this study the patients
were asked to generate the names of animals starting with the
above letters.
Logical memory test (Wechsler, 1987). This subtest from the
Wechsler Memory Scale–III, assesses verbal memory through
immediate recall, delayed recall and recognition tasks following
the examiner reading aloud a passage containing a short story to
the subject.
California verbal learning test (CVLT) (Delis et al., 1987). This
test of verbal learning and memory involves the oral presentation
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of a 16 word list and immediate recall of the same over five
trials. Free recall of the words was assessed again after a delay of
approximately 20 min. Afterwards, cued recall is tested by offering
the names of the four semantic categories to guide memory
retrieval, and yes–no recognition is assessed by embedding the 16
targets among 28 distractors.
n-back. The n-back task tests the effects of working memory load
on performance (Cohen et al., 1997; Perlstein et al., 2003; Owen
et al., 2005). In this task, a sequence of letters is presented to the
subjects, one at a time. Here, working memory load was either
two or three items, that is, subjects had to evaluate the similarity
of each item to the one presented n-items previously (n = 2 or 3).
In the two- and three-back conditions, a target was any letter that
was identical to the one presented two or three trials preceding
it, respectively. Stimulus encoding and response demands were
constant across conditions; only requirements to maintain and
update increasingly greater amounts of information at higher
loads differed. Pseudorandom sequences of single consonants
were presented, and subjects responded to each stimulus, pressing
one button to targets and another to no targets. Most subjects
did not learn the three-back condition, so we do not analyze it
any further in the study here, and focus on group differences and
medication effects on the two-back task.
Stroop color word test (Stroop, 1935). This test consists of a white
sheet of paper with blocks of colors printed on it in a matrix of
rows and columns. The subject in the first trial has to read out
the names of the colors in an order across rows or columns. In
the second trial, the subject is shown a paper with the names of
colors written in incongruous colors, again arranged in a matrix.
The subject has to suppress reading the print, but name the color
in which it is printed, again in the same serial order as before.
Each trials are timed separately and scores computed to assess the
color-word interference to study the executive functions such as
inhibition and cognitive flexibility.
Wisconsin card sorting test (WCST) (Heaton et al., 1993). This
test is used to assess the executive functions- set shifting and
category formation. The test consists of cards with geometric
patterns which the subject has to match based on a principal
he/she thinks is right. On receiving a feedback of right or wrong
across several trials, a subject learns to match the cards. The
category for matching is then shifted to another category at a
certain stage in the test without informing the subject. Number
and pattern of errors and correct responses reveals learning about
category formation and set shifting abilities.
Frontal assessment battery (FAB) (Dubois et al., 2000). The
FAB consists of six subtests assessing different functions related
to the frontal lobes such as: (1) conceptualization and abstract
reasoning (similarities test); (2) mental flexibility (verbal fluency
test); (3) motor programming and executive control of action
(Luria motor sequences); (4) resistance to interference (conflict-
ing instructions); (5) inhibitory control (go–no go test); and (6)
environmental autonomy (prehension behavior). The FAB has
shown a good validity (correlation of ρ = 0.82 with the Mattis
Dementia Rating Scale) and interrater reliability (κ = 0.87).
Affective and quality of life measures
We should not say additionally here as in the study design we have
already said we are looking into the effects/association of different
treatment on/with affective measures Beck Depression Inventory
was used to assess depressive symptoms (Beck et al., 1987), Beck
Anxiety Inventory (Beck et al., 1988) to assess anxiety, Apathy
evaluation scale (Marin et al., 1991) to assess apathy, and the
PDQ-39 (Jenkinson et al., 1995) questionnaire to assess quality
of life.
STATISTICAL ANALYSIS
For all analyses, we used SPSS as well as SAS v8.0 PROC MIXED.
One-way ANOVA was used to compare demographic and neu-
ropsychological measures between the PD patients on MAO-I
and levodopa, PD patients on monotherapy, and healthy control
subjects. Chi square statistic was used to compare the gender
ratio and the PD motor subttype (akinesia vs. tremor-dominant),
between the medicated PD patients, unmedicated PD patients,
and healthy controls groups.
Between-subject differences were examined using
unstructured covariance matrices which do not make any
strong assumptions about the variance and correlation of the
data unlike structured covariances. Where indicated, we tested
for specific planned contrasts. In these contrasts, the number of
degrees of freedom reflects the entire sample, and not just the
subjects involved in the particular contrast, because the mixed
procedure analyses between-subject effects, and controls for
other variables of interest that apply across all subjects. This
procedure uses all of the data to provide a more stable estimate
of the error term. Finally, we conducted interaction analysis of
medication regime (MAO-I and levodopa vs. monotherapy) and
subtype of PD patients (akinesia- vs. tremor-dominant) with all
neuropsychological and psychiatric measures.
RESULTS
Here, we first present results on the association of medication
types (multiple vs. monotherapy) on cognition. We then discuss
their differential effects on affective and quality of life measures.
Finally, we discuss the association of tremor vs. akinesia severity
on the same measures.
EFFECTS OF MAO-I AS AN ADJUNCT TO LEVODOPA ON COGNITION
Results show that PD patients on monotherapy were more
impaired than healthy subjects and PD patients on combined
MAO-I and levodopa in the probabilistic learning task (all p’s <
0.01, Figure 1A). There was no significant difference among the
healthy controls and PD groups in the deterministic learning task
(p > 0.1, Figure 1B).
In the case of patients who had MAO-I as an adjunct to
levodopa, their neuropsychological measures were better than
patients on monotherapy (Table 2). A significant difference was
noted on n-back task (p < 0.01), Backward digit span (p = 0.04),
Trail Making B (p = 0.031), FAB (p = 0.031), and WCST-64
(p = 0.04). There was no statistically significant difference among
the healthy controls and PD groups on other neuropsychological
measures (see Table 2).
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FIGURE 1 | Effects of combined MAO-B Inhibitors vs. monotherapy on
probabilistic and deterministic learning tasks. (A) Probabilistic learning
task. Data show that healthy subjects and PD patients on combined MAO-I
and levodopa show better performance than PD patients on monotherapy.
(B) Deterministic learning task. There was no significant difference among PD
and the healthy control groups in the deterministic learning task.
ASSOCIATION OF MAO-I AS AN ADJUNCT TO LEVODOPA ON
AFFECTIVE AND QUALITY OF LIFE MEASURES
As in the case of neuropsychological measures, patients who
had MAO-I as an adjunct to levodopa had better scores on
motivational processes than patients on monotherapy (Table 3).
Specifically, we found that compared to PD patients on
monotherapy, MAO-I as adjunct to levodopa show more bene-
ficial effects on mental health on the following measures: apathy
(p = 0.032), BDI (p = 0.031) and quality of life, as measured using
the PD-39 scale (p = 0.041). Although statistically nonsignificant,
unlike monotherapy, MAO-I as adjunct to levodopa seem to
better ameliorate anxiety (p = 0.09).
We further separated the levodopa and MAO-I group into
two groups (patients on rasagiline vs. others on selegiline), and
tested their performance on all questionnaires and cognitive tests.
There were no significant differences among the two groups
in any of the measures, except that in the rasagiline and lev-
odopa group, UPDRS scores were slightly but not significantly
lower than in patients in the selegiline and levodopa group
(p = 0.083).
INTERACTION OF MEDICATION REGIME WITH MOTOR SUBTYPE
On conducting an interaction analysis of medication regime
(MAO-I and levodopa vs. monotherapy) and subtype of PD
patients (akinesia- vs. tremor-dominant), the ameliorating effects
of MAO-I were more pronounced in PD patients with severe
akinesia than PD patients with predominant tremor. A significant
interaction was found between medication regime and subtype
Table 2 | Effects of combined MAO-B Inhibitors vs. monotherapy on cognition.
PD Patients on MAO Inhibitors PD Patients on Ldopa or Healthy Controls P-value
and Ldopa DA agonists only
Forward digit span 7.1 (1.7) 6.9 (1.4) 6.8 (1.9) 0.37
Backward digit span 7.9 (1.6) 6.12 (1.7) 8.2 (1.8) 0.04
Trail Making A 57.9 (6.3) 75.4 (7.0) 55.8 (6.9) 0.21
Trail Making B 104.1 (18.1) 142.3 (18.1) 94.4 (14.3) 0.031
Logical Memory, Delayed Recall 19.7 (7.2) 19.2 (8.1) 18.9 (6.8) 0.54
Logical Memory, Encoding 34.7 (10.9) 35.2 (11.2) 34.1 (12.1) 0.623
Verbal Fluency 18.7 (4.7) 19.6 (4.1) 20.3 (4.2) 0.58
Stroop Errors 5.31 (3.3) 5.1 (2.9) 4.9 (3.1) 0.41
FAB 13.69 (1.4) 10.6 (1.4) 14.1 (1.1) 0.031
CVLT-short delay free 7.0 (1.3) 6.9 (1.7) 7.2 (1.3) 0.21
CVLT-long delay free 6.9 (1.2) 6.81 (1.3) 6.9 (1.5) 0.29
CVLT-long delay cued 7.1 (1.0) 7.01 (1.4) 7.1 (1.3) 0.28
CVLT-delayed recognition 8.2 (0.8) 7.9 (0.9) 7.89 (1.3) 0.48
WCST-64 42.8 (10.1) 35.1 (9.3) 44.8 (12.2) 0.04
n-back 80.3 (3.35) 74.2 (3.54) 86.2 (3.71) 0.007
Abbreviations: FAB = Frontal Assessment Battery; NART Predicted IQ = National Adult Reading Test predicted intelligence; CVLT = California Verbal Learning Test;
WCST-64 = Wisconsin Card Sorting Test-64 cards version.
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Table 3 | Effects of combined MAO-B Inhibitors and levodopa vs. monotherapy on affective and quality of life measures.
PD Patients on MAO-B Inhibitors PD Patients on Ldopa or Healthy Controls P-value
and Ldopa DA agonists only
Apathy (Apathy evaluation scale) 32.6 (6.2) 39.8 (5.1) 33.4 (5.7) 0.032
Depression (BDI) 6.2 (1.2) 8.9 (1.1) 6.5 (1.9) 0.031
Anxiety (BAI) 14.3 (3.0) 17.2 (4.3) 13.3 (3.1) 0.09
Quality of life (PDQ-39) 29.8 (2.7) 25.3 (2.4) – 0.041
Abbreviations: BDI, Beck Depression Inventory; BAI, Beck Anxiety Inventory.
of PD patients on measures of Trail-Making B (p < 0.02), FAB
(p < 0.01), WCST (p < 0.04), BDI (p < 0.02), and apathy (p <
0.009). All other interaction effects (with neuropsychological and
psychiatric measures) were not significant (all p’s > 0.15).
DISCUSSION
Our results show MAO-B inhibitors as an adjunct to levodopa
provide a more enhancing effect than the use of monotherapy
(levodopa or DA agonists alone) on most cognitive, affective and
quality of life measures used in our study. Below, we discuss
the effects of MAO-B inhibitors as an adjunct to levodopa on
neuropsychiatric and cognitive measures.
EFFECTS OF MAO-B INHIBITORS ON COGNITIVE MEASURES
As mentioned above, there are very few studies that have inves-
tigated the effects of MAO-B inhibitors (taken alone or as an
adjunct to levodopa) on neuropsychological and cognitive mea-
sures. For example, rasagiline has been used to treat mild cognitive
impairment in PD (Goldman and Holden, 2014). A small study
involving seven patients on selegiline showed some improvement
in memory and motor speed without progressive memory loss
compared to those with dementia (Portin and Rinne, 1983).
Subsequently, Hietanen (1991) tested 18 patients with idiopathic
PD on selegiline as monotherapy for 8 weeks in a double blind
randomized placebo controlled trial, using a battery of neuropsy-
chological tests. The study found some improvement in learning
easy word associations, but did not find any significant specific
cognitive effect. As part of a multicenter trial of Deprenyl and
Tocopherol Antioxidative Therapy of Parkinsonism (DATATOP),
800 patients with early untreated PD were administered tests
that measured memory, visuospatial, and frontal lobe functions
(Kieburtz et al., 1994). The study did not find any significant
effect of either deprenyl (selegiline) or tocopherol on cognitive test
performance (Kieburtz et al., 1994). Further, in an 8-week study,
it was found that selegiline did not have an effect on executive
function using the Wisconsin Card Sorting Test (Dalrymple-
Alford et al., 1995). Recently, Hanagasi et al. (2011) found that
compared to placebo, the MAO-B inhibitor rasagiline has a better
effect on attention and executive function in nondemented PD
patients. In this double blind placebo controlled multicenter trial
of 48 non-demented patients with PD and cognitive impairment,
significant improvement was noticed in the rasagiline group on
scores of digit span backward, verbal fluency, semantic fluency,
Stroop, and attentional measures (Hanagasi et al., 2011).
Our results extend these findings by showing that MAO-B
inhibitors as an adjunct to levodopa have a better effect on
cognitive function (including probabilistic learning, forward and
backward digit span, n-back, WCST-64, FAB, Trail Making B)
in PD patients than levodopa or DA agonists monotherapy.
Unlike the Hanagasi et al. study, the present study employed
computerized cognitive tasks to assess learning in PD patients.
Our data show that patients who had MAO-B inhibitors as
adjunct to levodopa had better probabilistic but not deter-
ministic learning. Our results suggest that learning impair-
ment is exacerbated when the learning task involves uncer-
tain feedback and response conflict, as in the probabilistic, but
not deterministic, learning task. This interpretation is also in
agreement with prior research showing that PD patients show
impairments in conflict-based decision making tasks (Farooqui
et al., 2011; Vandenbossche et al., 2012). This also points to
the finding that probabilistic learning has a better potential to
reveal differences in drug effects than deterministic learning
tasks.
EFFECTS OF MAO-B INHIBITORS ON AFFECTIVE AND QUALITY OF LIFE
MEASURES
MAO inhibitors have been generally used as traditional antide-
pressant drugs (Johnson et al., 2010). For example, many studies
show that selegiline transdermal system help reduce depres-
sive symptoms in various patient populations (Bodkin and
Amsterdam, 2002; Amsterdam and Bodkin, 2006; Feiger et al.,
2006). In our study, we found that PD patients who were on
MAO-I and levodopa have lower BDI scores than patients on lev-
odopa or DA agonists alone, suggesting a beneficial effect of MAO
inhibitors on depression. Although not statistically significant,
we found that PD patients on MAO-I and levodopa have lower
scores on anxiety measure (as used by the Beck anxiety Inventory
questionnaire), when compared to patients on monotherapy.
Interestingly, we also found that PD patients who were on
MAO-I and levodopa have lower apathy and higher quality of life
scores than patients on levodopa or DA agonists alone, suggesting
a beneficial effect of MAO inhibitors on these measures.
INTERACTION BETWEEN MOTOR SUBTYPE IN PD AND MEDICATION
REGIME
We also found an interaction effect in the motor subtype, med-
ication and cognitive functions. Better cognitive functions were
seen more in patients with severe akinesia, in comparison to
patients with severe tremor. Our results extend prior studies
showing relationships between motor and cognitive measures in
PD (Riggeal et al., 2007; Colman et al., 2009; Wylie et al., 2012;
Smulders et al., 2013), and further show that the effects of MAO-I
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on neuropsychological, affective, and quality of life measures in
PD depends on the subtypes of PD.
Our results are also in line with prior studies showing that
PD patients with tremor are usually less cognitively impaired
than PD patients with akinesia or gait dysfunction (Vakil and
Herishanu-Naaman, 1998; Burn et al., 2006; Lyros et al., 2008;
Oh et al., 2009; Domellof et al., 2011). In addition, prior studies
have suggested that akinesia in PD patients is related to basal
ganglia dysfunction (Kassubek et al., 2002; Probst-Cousin et al.,
2003; Weinberger et al., 2009; Zaidel et al., 2009; Mure et al.,
2011). It is possible that in PD patients with severe akinesia,
the combined therapy of MAO inhibitors and levodopa has a
more ameliorative effect on basal ganglia dysfunction than lev-
odopa alone. We hypothesize that this effect can perhaps be due
to findings that tremor in PD is related to damage to brain
areas such as the cerebellum, while akinesia has been consis-
tently seen to be related to basal ganglia dysfunction (Mure
et al., 2011). Further, it is possible that MAO-B inhibitors
ameliorate the function of the basal ganglia and DA and thus
ameliorate impairment in PD patients with akinesia that is
patients with more cognitive damage get better effects from
treatment.
CONTINUOUS DOPAMINERGIC STIMULATION THEORY AND
BIOAVAILABILITY OF MONOAMINES
The beneficial effects of MAO-I can be due to the Contin-
uous Dopaminergic Stimulation (CDS) of the basal ganglia
and/or an increase in the bioavailability of monoamines. The
CDS theory posits that sufficient dopaminergic stimulation of
the basal ganglia (and particularly the striatum) reduces the
occurrence of motor complications (such as wearing-off phe-
nomenon) and dyskinesia (Nyholm, 2007; Silverdale, 2007). A
multitude of studies have shown that these motor complications
are associated with the administration of levodopa medica-
tions, and that combined therapies (levodopa with DA ago-
nists, COMT inhibitors, or MAO inhibitors) can reduce these
motor fluctuations (Jankovic and Stacy, 2007; Stocchi et al.,
2008).
Alternatively, many studies have shown that MAO-I can
increase the levels of many monoamines including DA, serotonin,
and norepinephrine (Riederer and Laux, 2011). Most of these
monoamines are known to impact cognitive and psychiatric
measures in various patient populations, and thus the beneficial
effects of MAO-I on our patients could be due to an increase of
monoamine levels in the brain (Hamon and Blier, 2013).
Our results extend these findings, and show that the bene-
ficiary effects of levodopa and MAO-I can also be observed in
cognitive, affective and quality of life measures. It is possible
that MAO-I and levodopa enhance DA and other monoamine
neurotransmission and thus provide a continuous stimulation of
the basal ganglia, which in turn, ameliorate neuropsychological,
affective and quality of life dysfunction in PD patients. None
of our patients were on COMT inhibitors, but future studies
should evaluate whether COMT inhibitors (taken alone or in
combination with levodopa) also ameliorate neuropsychiatric and
neuropsychological function in PD patients, in comparison to
monotherapy.
LIMITATIONS
Our study is not without limitations. Our samples included a
small number of subjects to compare PD patients on levodopa
to patients on DA agonists alone. There are very few number
of PD patients on DA agonists (either alone or in combination
with other medications). A future study recruiting patients on DA
agonists and/or MAO-B inhibitors can help understand its effects
on motor, psychiatric, and cognitive processes in comparison to
levodopa and/or MAO-B inhibitors. Similarly, we did not have
a large sample of PD patients to compare differential effects of
selegiline vs. rasagiline on neurocognitive and neuropsychiatric
measures. Further, a longitudinal study is needed to confirm
findings that the administration of MAO-I and levodopa better
ameliorate and cognitive abnormalities than the administration
of levodopa alone.
Overall, our results show that combination therapy of MAO
inhibitors and levodopa are associated with better neuropsycho-
logical, cognitive, and affective function in PD patients than
levodopa or DA agonists alone. To our knowledge, this is the first
study to investigate the effects of MAO inhibitors on cognitive
as well as classical neuropsychological tests in PD patients using
computerized learning tests.
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